Startseite Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women

  • Jean-Claude Forest , Sébastien Thériault , Jacques Massé , Emmanuel Bujold und Yves Giguère EMAIL logo
Veröffentlicht/Copyright: 18. Februar 2014
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 52 Heft 8

Abstract

Background: This study aims to evaluate the performance of the soluble Fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio to predict early-onset, preterm and severe preeclampsia at mid-pregnancy in asymptomatic women.

Methods: Based on a prospective cohort of 7929 pregnant women from the Quebec City metropolitan area, a nested case-control study was performed including 111 women who developed preeclampsia and 69 women with gestational hypertension matched with 338 normotensive women. Serum sFlt-1 and PlGF were measured between 20 and 32 weeks of gestation. The performance of the sFlt-1/PlGF ratio, expressed as raw values and multiples of the median (MoM) for the prediction of early-onset, preterm and severe preeclampsia was evaluated.

Results: Women who developed preeclampsia had significantly higher MoM sFlt-1/PlGF ratio (p<0.001). In the early-onset preeclampsia group, the median of the MoM distribution was 24.0 and the area under the receiver operating characteristic curve (AUC) was 0.977, giving sensitivities of 77.8% and 88.9% at false-positive rates of 5% and 10%. Positive predictive values (PPV) were 2.5% and 1.5%, respectively. In a subset between 26 and 32 weeks of gestation, at a threshold of 30, the sFlt-1/PlGF ratio yielded 100% specificity and identified, respectively, 85.7% and 65.2% of women who developed early-onset and preterm preeclampsia.

Conclusions: The sFlt-1/PlGF ratio has the potential to predict early-onset and preterm preeclampsia at mid-pregnancy in asymptomatic women. However, care must be paid to the prevalence of early-onset preeclampsia in the population since low prevalence reduces PPV and may hamper clinical utility.

Keywords: mid-pregnancy; placental growth factor; prediction; preeclampsia; soluble Fms-like tyrosine kinase-1
Corresponding author: Yves Giguère, MD, PhD, FRCPC, CHU de Québec Research Center, Hôpital St-François d’Assise, 10, rue de l’Espinay, Québec City, Québec, G1L 3L5, Canada, Phone: +1 418 525 4444 ext. 53712, Fax: +1 418 525 4195, E-mail:

Acknowledgments

Automated immunoassay analyzer and reagents for PlGF were provided by PerkinElmer Life and Analytical Sciences. We would like to thank Nathalie Bernard, Mylène Badeau and Véronique Goulet for their professional assistance in the project, and our research nurses for the recruitment of participants and retrieval of data from the medical records.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research funding played no role in thestudy design; in the collection, analysis, and interpretationof data; in the writing of the report; or in the decision tosubmit the report for publication.

Research funding: This work was supported by the Canadian Institutes of Health Research (CIHR, Healthy Pregnancy Initiative from the Institute for Human Development, Child and Youth Health).

Employment or leadership: YG is a research scholar from the Fonds de la recherche du Québec – Santé (FRQ-S). EB holds a Clinician Scientist Award from the CIHR and the Jeanne et Jean-Louis Lévesque Perinatal Research Chair at Université Laval.

Honorarium: None declared.

References

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–7.10.1053/j.semperi.2009.02.010Suche in Google Scholar

2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631–44.10.1016/S0140-6736(10)60279-6Suche in Google Scholar

3. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. Am J Hypertens 2008;21:521–6.10.1038/ajh.2008.20Suche in Google Scholar PubMed

4. Rao AK, Cheng YW, Caughey AB. Perinatal complications among different Asian-American subgroups. Am J Obstet Gynecol 2006;194:e39–41.10.1016/j.ajog.2006.01.027Suche in Google Scholar PubMed

5. Silva LM, Coolman M, Steegers EA, Jaddoe VW, Moll HA, Hofman A, et al. Low socioeconomic status is a risk factor for preeclampsia: the Generation R Study. J Hypertens 2008;26:1200–8.10.1097/HJH.0b013e3282fcc36eSuche in Google Scholar PubMed

6. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001;97:533–8.Suche in Google Scholar

7. Murphy DJ, Stirrat GM. Mortality and morbidity associated with early-onset preeclampsia. Hypertens Pregnancy 2000;19:221–31.10.1081/PRG-100100138Suche in Google Scholar PubMed

8. Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013;61:932–42.10.1161/HYPERTENSIONAHA.111.00250Suche in Google Scholar PubMed

9. James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol 2010;221:363–78.10.1002/path.2719Suche in Google Scholar PubMed

10. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993;91:950–60.10.1172/JCI116316Suche in Google Scholar PubMed PubMed Central

11. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Ann Rev Med 2008;59:61–78.10.1146/annurev.med.59.110106.214058Suche in Google Scholar PubMed

12. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705–9.10.1073/pnas.90.22.10705Suche in Google Scholar PubMed PubMed Central

13. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007;196:396 e1–7; discussion e7.10.1016/j.ajog.2006.12.024Suche in Google Scholar PubMed

14. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58.10.1172/JCI17189Suche in Google Scholar PubMed PubMed Central

15. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998;59:1540–8.10.1095/biolreprod59.6.1540Suche in Google Scholar PubMed

16. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306–9.10.1126/science.2479986Suche in Google Scholar PubMed

17. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991;88:9267–71.10.1073/pnas.88.20.9267Suche in Google Scholar PubMed PubMed Central

18. Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012;58:837–45.10.1373/clinchem.2011.169094Suche in Google Scholar PubMed

19. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012;59:740–6.10.1161/HYPERTENSIONAHA.111.181735Suche in Google Scholar PubMed

20. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3–18.10.1080/14767050400028816Suche in Google Scholar PubMed

21. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New Engl J Med 2006;355: 992–1005.10.1056/NEJMoa055352Suche in Google Scholar PubMed

22. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004;350:672–83.10.1056/NEJMoa031884Suche in Google Scholar

23. Villa PM, Hamalainen E, Maki A, Raikkonen K, Pesonen AK, Taipale P, et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth 2013;13:110.10.1186/1471-2393-13-110Suche in Google Scholar

24. Leanos-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leanos R, Romero-Arauz JF, Ayala-Mendez JA, et al. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. J Hypertens 2012;30:2173–81.10.1097/HJH.0b013e328357c0c9Suche in Google Scholar

25. Crispi F, Llurba E, Dominguez C, Martin-Gallan P, Cabero L, Gratacos E. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;31:303–9.10.1002/uog.5184Suche in Google Scholar

26. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am Journal Obstet Gynecol 2007;197:244e1–8.10.1016/j.ajog.2007.06.030Suche in Google Scholar

27. McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012;207:407e1–7.10.1016/j.ajog.2012.08.010Suche in Google Scholar

28. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. Br J Obstet Gynaecol 2012;119:778–87.10.1111/j.1471-0528.2012.03311.xSuche in Google Scholar

29. Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008;30:S1–48.10.1016/S1701-2163(16)32870-5Suche in Google Scholar

30. Ohkuchi A, Hirashima C, Matsubara S, Takahashi K, Matsuda Y, Suzuki M. Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension 2011;58:859–66.10.1161/HYPERTENSIONAHA.111.174417Suche in Google Scholar PubMed

31. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38.10.3109/14767050902994754Suche in Google Scholar PubMed PubMed Central

32. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011;205:469e1–8.10.1016/j.ajog.2011.06.058Suche in Google Scholar PubMed

33. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010;33:422–7.10.1038/hr.2010.15Suche in Google Scholar PubMed

34. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010;202:40e1–7.10.1016/j.ajog.2009.07.025Suche in Google Scholar PubMed

35. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161e1–11.10.1016/j.ajog.2009.09.016Suche in Google Scholar PubMed

36. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. Br Med J 2011;342:d1875.10.1136/bmj.d1875Suche in Google Scholar PubMed PubMed Central

37. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187–207.10.3109/14767058.2011.589932Suche in Google Scholar PubMed PubMed Central

38. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58e1–8.10.1016/j.ajog.2011.07.037Suche in Google Scholar PubMed

39. Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013;32:189–201.10.3109/10641955.2013.784788Suche in Google Scholar PubMed PubMed Central

40. Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012;25:2651–7.10.3109/14767058.2012.713055Suche in Google Scholar PubMed

41. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–9.10.1161/CIRCULATIONAHA.111.054361Suche in Google Scholar PubMed PubMed Central

42. Cifuentes J, Bronstein J, Phibbs CS, Phibbs RH, Schmitt SK, Carlo WA. Mortality in low birth weight infants according to level of neonatal care at hospital of birth. Pediatrics 2002;109:745–51.10.1542/peds.109.5.745Suche in Google Scholar PubMed

43. Sanderson M, Sappenfield WM, Jespersen KM, Liu Q, Baker SL. Association between level of delivery hospital and neonatal outcomes among South Carolina Medicaid recipients. Am J Obstet Gynecol 2000;183:1504–11.10.1067/mob.2000.107357Suche in Google Scholar PubMed

Received: 2013-11-5
Accepted: 2014-1-16
Published Online: 2014-2-18
Published in Print: 2014-8-1

©2014 by Walter de Gruyter Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Colorectal cancer and screening programs: not only analytical issues
  4. Reviews
  5. Laboratory diagnostics of inherited platelet disorders
  6. Reticulated platelets: analytical aspects and clinical utility
  7. Genetics and Molecular Diagnostics
  8. Advanced tools for BRCA1/2 mutational screening: comparison between two methods for large genomic rearrangements (LGRs) detection
  9. General Clinical Chemistry and Laboratory Medicine
  10. Establishing, harmonizing and analyzing critical values in a large academic health center
  11. Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations
  12. First fully automated immunoassay for anti-Müllerian hormone
  13. A multicenter evaluation of dysthyroxinemia in a defined patient cohort
  14. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis
  15. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women
  16. Development of a new immunoassay for the detection of ethyl glucuronide (EtG) in meconium: validation with authentic specimens analyzed using LC-MS/MS. Preliminary results
  17. Optimizing centrifugation of coagulation samples in laboratory automation
  18. Evaluation of the automated coagulation analyzer CS-5100 and its utility in high throughput laboratories
  19. A new sampling device for faecal immunochemical testing: haemoglobin stability is still an open issue
  20. Reference Values
  21. Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screening
  22. Cancer Diagnostics
  23. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients
  24. Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium
  25. Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas
  26. Letters to the Editor
  27. Further comments on “Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation”
  28. A questionnaire study among nurses: awareness of blood and urine sample collection procedures
  29. Measurement uncertainty and clinical interpretation of measurement results
  30. Laboratory automation: how will you select the boarding assays?
  31. Improvement and evaluation of a 1,2-dioleoylglycerol method for measuring pancreatic lipase catalytic activity in serum
  32. The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family
  33. 1,5 Anhydroglucitol serum concentration as a biomarker for screening gestational diabetes in early pregnancy
  34. A rare condition: IgE type monoclonal gammopathy of undetermined significance
  35. Laboratory analysis of intraosseous blood: bad to the bone?
https://doi.org/10.1515/cclm-2013-0955
Schlagwörter für diesen Artikel
mid-pregnancy; placental growth factor; prediction; preeclampsia; soluble Fms-like tyrosine kinase-1

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Colorectal cancer and screening programs: not only analytical issues
  4. Reviews
  5. Laboratory diagnostics of inherited platelet disorders
  6. Reticulated platelets: analytical aspects and clinical utility
  7. Genetics and Molecular Diagnostics
  8. Advanced tools for BRCA1/2 mutational screening: comparison between two methods for large genomic rearrangements (LGRs) detection
  9. General Clinical Chemistry and Laboratory Medicine
  10. Establishing, harmonizing and analyzing critical values in a large academic health center
  11. Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations
  12. First fully automated immunoassay for anti-Müllerian hormone
  13. A multicenter evaluation of dysthyroxinemia in a defined patient cohort
  14. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis
  15. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women
  16. Development of a new immunoassay for the detection of ethyl glucuronide (EtG) in meconium: validation with authentic specimens analyzed using LC-MS/MS. Preliminary results
  17. Optimizing centrifugation of coagulation samples in laboratory automation
  18. Evaluation of the automated coagulation analyzer CS-5100 and its utility in high throughput laboratories
  19. A new sampling device for faecal immunochemical testing: haemoglobin stability is still an open issue
  20. Reference Values
  21. Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screening
  22. Cancer Diagnostics
  23. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients
  24. Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium
  25. Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas
  26. Letters to the Editor
  27. Further comments on “Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation”
  28. A questionnaire study among nurses: awareness of blood and urine sample collection procedures
  29. Measurement uncertainty and clinical interpretation of measurement results
  30. Laboratory automation: how will you select the boarding assays?
  31. Improvement and evaluation of a 1,2-dioleoylglycerol method for measuring pancreatic lipase catalytic activity in serum
  32. The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family
  33. 1,5 Anhydroglucitol serum concentration as a biomarker for screening gestational diabetes in early pregnancy
  34. A rare condition: IgE type monoclonal gammopathy of undetermined significance
  35. Laboratory analysis of intraosseous blood: bad to the bone?
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 17.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2013-0955/html
Button zum nach oben scrollen